Related references
Note: Only part of the references are listed.New treatment for acute myelogenous leukemia
Courtney D. DiNardo et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Efficacy and Mechanism of Action of Volasertib, a Potent and Selective Inhibitor of Polo-Like Kinases, in Preclinical Models of Acute Myeloid Leukemia
Dorothea Rudolph et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
Hartmut Doehner et al.
BLOOD (2014)
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
C-C Lin et al.
BRITISH JOURNAL OF CANCER (2014)
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2012)
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes
Thomas Force et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Questions Regarding Frontline Therapy of Acute Myeloid Leukemia
Hagop Kantarjian et al.
CANCER (2010)
Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics
Puneet Chopra et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
Klaus Strebhardt
NATURE REVIEWS DRUG DISCOVERY (2010)
Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells
Annelies G. Renner et al.
BLOOD (2009)
BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
Dorothea Rudolph et al.
CLINICAL CANCER RESEARCH (2009)
Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology
Patrick Schoffski
ONCOLOGIST (2009)
Biology and management of relapsed acute myeloid leukaemia
C Craddock et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Polo-like kinases (Plks) and cancer
N Takai et al.
ONCOGENE (2005)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
